Table 1.
Summary of estimated growth delay (T-C), doubling time (Td), and surviving fraction as a percent (100×exp(−(T–C)×B), with bootstrap 95% CI), log cell kill method, by experiment and treatment arm in DB-1 human melanoma xenografts in absence and presence of hyperglycemia.
| Treatments | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LND | LPAM | LND+LPAM | ||||||||||
|
| ||||||||||||
| Parameters | Without Glucose | With Glucose | SE | p value | Without Glucose | With Glucose | SE | p value | Without Glucose | With Glucose | SE | p value |
| T-C | 1.99 d | 1.70 d | 2.50 | 0.91 | 7.62 d | 0.29 d | 3.74 | 0.05 | 17.75 d | 7.76 d | 2.82 | < 0.001 |
| Td | 6.50 d | 9.36 d | 100.29 | 0.98 | 5.91 d | 5.83 d | 1.49 | 0.96 | 5.32 d | 5.31 d | 0.38 | 0.98 |
| % Surviving fraction | 81 (46, 158) | 88 (51, 129) | 22 | 0.75 | 41 (13,108) | 97 (38, 192) | 56 | 0.32 | 10 (4, 28) | 36 (16, 77) | 15 | 0.08 |
NOTE: LND: Lonidamine; LPAM: Melphalan; T: median time (in days) required for the treatment group tumors to reach a predetermined size; C: median time (in days) for the control group tumors to reach the same size; B: average slope across both arms of the study; SE: standard error of the difference (27).